---
title: "Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302438355.md"
description: "Scinai Immunotherapeutics (SCNI) extended its cash runway to late 2027 through a new CDMO agreement and equity financing. Committed customer orders rose to $8.1 million, with the deal valued at over $5.1 million in base fees. Recent capital raises totaled $5.3 million. Despite improved liquidity, Spark AI rates SCNI as Neutral due to weak financials, negative gross profit, and bearish technical signals."
datetime: "2026-10-20T14:32:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302438355.md)
  - [en](https://longbridge.com/en/news/302438355.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302438355.md)
generator: "portal-rs"
---

# Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing

Scinai Immunotherapeutics ( (SCNI) ) just unveiled an update.

On October 20, 2026, Scinai Immunotherapeutics reported that a new CDMO agreement with a U.S.-based Nasdaq-listed biopharmaceutical client and recently completed equity financings have significantly expanded its contracted business and strengthened liquidity. The new contract lifts Committed Customer Orders to about $8.1 million from $1.9 million at year-end 2025, while management now estimates its operating runway extends to late 2027, with potential for further extension if later project phases are activated.

The CDMO agreement provides approximately $5.1 million in committed base service fees and could exceed $10 million when including uncommitted later phases, underscoring Scinai’s competitive positioning after winning the work over larger CDMOs. Recent capital raises, totaling about $5.3 million in net proceeds, together with expected customer payments, are intended to fund execution of current projects, improve facility utilization, support pursuit of additional CDMO contracts in the U.S. and Europe, and allow continued but selective advancement of its NanoAb immunotherapy programs with a focus on achieving sustainable profitability.

**Spark’s Take on SCNI Stock**

According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.

The score is held down primarily by weak financial performance (negative gross profit, large operating losses, and persistent cash burn) and a bearish technical setup (price far below key moving averages with negative momentum). The latest earnings call adds some support due to early commercial traction and committed orders, but near-term liquidity constraints and potential dilution risk remain key overhangs. Valuation inputs are insufficient to materially improve the score.

To see Spark’s full report on SCNI stock,  
 click here. 

**More about Scinai Immunotherapeutics**

Scinai Immunotherapeutics is an Israel-based biopharmaceutical company listed on Nasdaq that is building a contract development and manufacturing organization (CDMO) business alongside an immunotherapy platform. Its CDMO unit focuses on development and manufacturing services for pharmaceutical clients, while its therapeutic pipeline centers on NanoAb-based IL-17 programs developed with academic partners in Germany.

**Average Trading Volume:** 2,142,508

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $427.5K

### Related Stocks

- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)

## Related News & Research

- [Scinai Immunotherapeutics Secures $5.1 Million CDMO Deal, Tripling Committed Orders](https://longbridge.com/en/news/301710899.md)
- [Scinai signs USD 5.1 million CDMO development, clinical manufacturing agreement](https://longbridge.com/en/news/301700419.md)
- [AEHR: Record $33.0m quarter; FY27 revenue outlook raised to $150m on strong AI demand](https://longbridge.com/en/news/304010185.md)
- [Scinai Immunotherapeutics Secures $4 Million via Private Placement and Warrant Inducement](https://longbridge.com/en/news/301996939.md)
- [Palantir Q3 revenue jumps 96%, beats analyst expectations](https://longbridge.com/en/news/304009150.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**